Brian M. Wolpin
researcher, ORCiD ID=0000-0002-0455-1032
5 stories
12 quotes
That time was not built into my talk,
- Wolpin quipped from the stage once the ovation finally subsidedNewsweeknewsweek.com/new/cancer…
Based on the data we have now, I think this drug is relevant to all patients with pancreatic cancer, assuming that they have metastatic cancer,
- Wolpin saidNBC Newsnbcnews.com/health/health…
It’s been incredibly hard to drug that mutation,
- Wolpin saidNBC Newsnbcnews.com/health/health…
Pancreatic ductal adenocarcinoma is among the most challenging and lethal cancers, with limited therapeutic options,
- recalled Brian Wolpin, lead investigator of the trial at Dana-Farber Cancer Institute in Boston, Massachusetts, on Sunday in ChicagoLe Mondelemonde.fr/en/science…
These results will change how scientists, clinicians, and patients think about treatment for pancreatic cancer,
- said Dr. Brian Wolpin of Harvard's Dana-Farber Cancer Institute and principal investigator of the trialReutersreuters.com/business/healthcar…
Pancreas cancer may be the first for this drug, but there will be others,
- said Dr. Brian Wolpin, who also led research on daraxonrasib and directs the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer InstituteNBC Newsnbcnews.com/health/health…
Earlier
Revolution Medicines' new cancer pill extends life: ‘Molecular glue’ works, study shows
Hindustan Timeshindustantimes.com/world/news…It blocks a mutated protein that fuels tumor growth in more than 90 percent of pancreatic cancer cases—a target that had eluded treatment for decades
Newsweeknewsweek.com/new/cancer…After new drug’s ‘unprecedented’ results for pancreatic cancer, doctors look at other uses
NBC Newsnbcnews.com/health/health…The findings were published in the New England Journal of Medicine and presented Sunday at the American Society for Clinical Oncology meeting in Chicago
CNBCcnbc.com/2026/05…Promising drug found to double survival rate for advanced pancreatic cancer patients
The Independentindependent.co.uk/news/science…The report from a first-in-human trial of daraxonrasib is the first peer-reviewed paper to show safety data for what analysts say could become the next standard of care for previously treated metastatic pancreatic cancer
Reutersreuters.com/business/healthcar…Revolution Medicines' experimental cancer pill helps improve survival in late-stage study
Reutersreuters.com/business/healthcar…Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial
CNBCcnbc.com/2026/04…RevMed’s Cancer Drug Nearly Doubles Overall Survival in Pivotal Study
Bloomberg Newsbloomberg.com/news/articles…